Brolucizumab is an anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.
- Mechanism
- Curator reviewed · 4 references
Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.
- Primary indication
- Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.Curator reviewed · 1 structured indication
- Formula / weight
- 26000.0 Da (approximate)
- First approval
- Canada, 2020 · United States, 2019 · European Union, 2020
- Also known as
- brolucizumab-dbll
- Code names
- ESBA-1008 · RTH-258
- Brand names
Resolves to
Compound
Clinical / RWD
Targets
What you can answer from here — as of September 06, 2024
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Brolucizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account